Literature DB >> 12708489

Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers.

Takao Takahashi1, Bun Sano, Takayasu Nagata, Hiroki Kato, Yasuyuki Sugiyama, Katsuyuki Kunieda, Masashi Kimura, Yukio Okano, Shigetoyo Saji.   

Abstract

PLK (polo-like kinase), the human counterpart of polo in Drosophila melanogaster and of CDC5 in Saccharomyces cerevisiae, belongs to a family of serine/threonine kinases. It is intimately involved in spindle formation and chromosome segregation during mitosis. The purpose of this study was to determine whether PLK1 is overexpressed in primary colorectal cancer specimens as compared with normal colon mucosa and to assess its relation to other kinases as a potential new tumor marker. In the present study, immunohistochemical analyses were performed of PLK1 expression in 78 primary colorectal cancers as well as 15 normal colorectal specimens. Furthermore, we examined the relationship between other kinases, Aurora-A and Aurora-C, and PLK1 expression. In normal colon mucosa, some crypt cells showed weakly positive staining for PLK1 in 13 out of 15 cases, the remaining cases being negative. Elevated expression of PLK1 was observed in 57 (73.1%) of the colorectal cancers, statistically significant associations being evident with pT (primary tumor invasion) (P=0.0006, Mann-Whitney U test), pN (regional lymph nodes) (P=0.008, chi2 test) and the Dukes' classification (P=0.0005, Mann-Whitney U test). Mean proliferating cell nuclear antigen-labeling index was 52.3%, with a range of 24.1% to 77.3%. Values for lesions with high and low PLK1 expression were 54.7+/-10.3% (mean+/-SD) and 45.9+/-11.9% (P=0.002, Student's t test). PLK1 was significantly associated with Aurora-A, but PLK1 staining was more diffuse and extensive than for Aurora-A or Aurora-C. Interestingly, PLK1 overexpression was significantly associated with p53 accumulation in colorectal cancers. Our results suggest overexpression of PLK1 might be of pathogenic, prognostic and proliferative importance, so that this kinase might have potential as a new tumor marker for colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12708489     DOI: 10.1111/j.1349-7006.2003.tb01411.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  87 in total

1.  Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.

Authors:  Tetsuo Ito; Fumiaki Sato; Takatsugu Kan; Yulan Cheng; Stefan David; Rachana Agarwal; Bogdan C Paun; Zhe Jin; Alexandru V Olaru; James P Hamilton; Florin M Selaru; Jian Yang; Nobutoshi Matsumura; Kazuharu Shimizu; John M Abraham; Yutaka Shimada; Yuriko Mori; Stephen J Meltzer
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

2.  An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication.

Authors:  Syed Mohd Danish Rizvi; Abdulaziz Arif A Alshammari; Waleed Abdullah Almawkaa; Abo Bakr F Ahmed; Ahmed Katamesh; Ahmed Alafnan; Tariq J Almutairi; Rakan F Alshammari
Journal:  3 Biotech       Date:  2019-02-09       Impact factor: 2.406

3.  Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

Authors:  Weijuan Yan; Huijie Yu; Wei Li; Fengsheng Li; Sinian Wang; Nan Yu; Qisheng Jiang
Journal:  Oncol Lett       Date:  2018-09-14       Impact factor: 2.967

4.  Autoinhibition and relief mechanism for Polo-like kinase 4.

Authors:  Joseph E Klebba; Daniel W Buster; Tiffany A McLamarrah; Nasser M Rusan; Gregory C Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 5.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

6.  An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.

Authors:  Walter M Stadler; David J Vaughn; Guru Sonpavde; Nicholas J Vogelzang; Scott T Tagawa; Daniel P Petrylak; Peter Rosen; Chia-Chi Lin; John Mahoney; Sanjiv Modi; Peter Lee; Marc S Ernstoff; Wu-Chou Su; Alexander Spira; Korinna Pilz; Richard Vinisko; Charles Schloss; Holger Fritsch; Charles Zhao; Michael A Carducci
Journal:  Cancer       Date:  2013-12-11       Impact factor: 6.860

7.  Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Authors:  Neil E Bhola; Valerie M Jansen; Sangeeta Bafna; Jennifer M Giltnane; Justin M Balko; Mónica V Estrada; Ingrid Meszoely; Ingrid Mayer; Vandana Abramson; Fei Ye; Melinda Sanders; Teresa C Dugger; Eliezer V Allen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

Review 8.  Study of apoptosis-related interactions in colorectal cancer.

Authors:  Himanshu Arora; Rehana Qureshi; M A Rizvi; Sharad Shrivastava; Mordhwaj S Parihar
Journal:  Tumour Biol       Date:  2016-09-15

9.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

10.  Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors.

Authors:  Norman L Lehman; Rob Tibshirani; Jerry Y Hsu; Yasodha Natkunam; Brent T Harris; Robert B West; Marilyn A Masek; Kelli Montgomery; Matt van de Rijn; Peter K Jackson
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.